Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 9, 2026, 11:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 231 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Safety and Tolerability in Elderly Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older Adults

NCT05297578
View directory record Official record
Conditions
Pneumococcal Vaccines
Interventions
24-Valent Pneumococcal Conjugate Vaccine, Pneumococcal 20-valent Conjugate Vaccine
Biological
Lead sponsor
Vaxcyte, Inc.
Industry
Eligibility
65 Years and older
Enrollment
207 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
20
States / cities
Birmingham, Alabama • DeLand, Florida • Hollywood, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Jun 9, 2026, 11:40 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants

NCT05584202
View directory record Official record
Conditions
SARS-CoV-2
Interventions
mRNA-1273.214, Placebo
Biological · Other
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
2 Months to 6 Months
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
39
States / cities
Bessemer, Alabama • Birmingham, Alabama • Tucson, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Jun 9, 2026, 11:40 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of ORX142 in Healthy Adult Subjects, Including Subjects 18 to 80 Years of Age

NCT07082829
View directory record Official record
Conditions
Excessive Daytime Sleepiness
Interventions
ORX142 Tablets, Placebo Tablets
Drug · Other
Lead sponsor
Centessa Pharmaceuticals (UK) Limited
Industry
Eligibility
18 Years to 80 Years
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
Lincoln, Nebraska • Eatontown, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Jun 9, 2026, 11:40 PM EDT
Completed Phase 3 Interventional

A Fifty-two-week Study to Evaluate the Safety of Saredutant in Adult and Elderly Patients With Depression

NCT00250653
View directory record Official record
Conditions
Depressive Disorder
Interventions
Saredutant succinate (SR48968C)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 16, 2012 · Synced Jun 9, 2026, 11:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PA-001 Ph.1 Study in Healthy and Elderly Subjects

NCT07518771
View directory record Official record
Conditions
COVID - 19
Interventions
PA-001
Drug
Lead sponsor
PeptiDream Inc.
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Jun 9, 2026, 11:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Varenicline Safety, Tolerability, Pharmacokinetics and Pro-Cognitive Effects in Healthy Elderly Non-Smoking Subjects

NCT00694044
View directory record Official record
Conditions
Healthy, Non-Smoking
Interventions
varenicline, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
65 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jun 1, 2009 · Synced Jun 9, 2026, 11:40 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study Evaluating PAZ-417 in Healthy Young/Elderly

NCT00366288
View directory record Official record
Conditions
Alzheimer Disease
Interventions
PAZ-417
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 9, 2009 · Synced Jun 9, 2026, 11:40 PM EDT
Terminated Phase 2 Interventional Results available

A Study of the Effects of CY6463 in Participants With Alzheimer's Disease With Vascular Pathology

NCT04798989
View directory record Official record
Conditions
Alzheimer's Disease With Vascular Pathology
Interventions
CY6463, Placebo
Drug
Lead sponsor
Tisento Therapeutics
Industry
Eligibility
60 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
Scottsdale, Arizona • Miami, Florida • Honolulu, Hawaii + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Jun 9, 2026, 11:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Dose Study to Assess the Safety, Effects, and Blood and Urine Drug Levels of AZD3293 in Healthy Subjects

NCT01739647
View directory record Official record
Conditions
Healthy Young Volunteers, Healthy Elderly Volunteers
Interventions
AZD3293, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 26, 2013 · Synced Jun 9, 2026, 11:40 PM EDT
Completed Phase 2 Interventional

Safety and Anti-Disease Activity of Oral Tosedostat (CHR-2797) in Elderly Subjects With Refractory or Relapsed AML

NCT00780598
View directory record Official record
Conditions
Acute Myeloid Leukemia, AML
Interventions
Tosedostat
Drug
Lead sponsor
Chroma Therapeutics
Industry
Eligibility
60 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
17
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Orlando, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2012 · Synced Jun 9, 2026, 11:40 PM EDT
Completed Phase 3 Interventional

Long-term Safety Study of Chronocort in the Treatment of Participants With Congenital Adrenal Hyperplasia

NCT05299554
View directory record Official record
Conditions
Congenital Adrenal Hyperplasia
Interventions
Chronocort
Drug
Lead sponsor
Neurocrine UK Limited
Industry
Eligibility
16 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
11
States / cities
Los Angeles, California • Orange, California • Jacksonville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Jun 9, 2026, 11:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of Xanomeline With Trospium Chloride Versus KarXT in Healthy Adult and Elderly Participants of Japanese Ethnicity and to Assess the Effect of Omeprazole on the PK of Xanomeline With Trospium Chloride in Healthy Adult Participants

NCT06605950
View directory record Official record
Conditions
Healthy Volunteers
Interventions
KarXT, KarX-EC, Placebo, Omeprazole
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
19 Years to 90 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Jun 9, 2026, 11:40 PM EDT
Terminated Phase 1 Interventional

Study of Talaporfin Sodium Photodynamic Therapy to Treat Advanced Age Related Macular Disease

NCT00102115
View directory record Official record
Conditions
Macular Degeneration, Choroidal Neovascularization
Interventions
Talaporfin Sodium (LS11) Photodynamic Therapy (PDT)
Drug
Lead sponsor
Light Sciences LLC
Industry
Eligibility
50 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 11, 2010 · Synced Jun 9, 2026, 11:40 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Safety and Tolerability of a Recombinant Herpes Zoster Vaccine

NCT05750017
View directory record Official record
Conditions
Herpes Zoster, Vaccine-Preventable Diseases
Interventions
Low Dose Recombinant Herpes Zoster Vaccine (LZ901), High Dose Recombinant Herpes Zoster Vaccine (LZ901), Placebo
Biological · Drug
Lead sponsor
Beijing Luzhu Biotechnology Co., Ltd.
Other
Eligibility
50 Years to 70 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 26, 2023 · Synced Jun 9, 2026, 11:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Escalating Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LNK 754 in Elderly Volunteers and in Subjects With Mild Alzheimer's Disease

NCT01013610
View directory record Official record
Conditions
Mild Alzheimer's Disease
Interventions
LNK-754, Placebo
Drug
Lead sponsor
Link Medicine Corporation
Industry
Eligibility
55 Years and older
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
7
States / cities
Phoenix, Arizona • Long Beach, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2011 · Synced Jun 9, 2026, 11:40 PM EDT
Completed Phase 3 Interventional

An Eight-week Study Evaluating the Efficacy of a 100mg Dose of Saredutant Once Daily, in Elderly Patients With Major Depressive Disorder

NCT00415142
View directory record Official record
Conditions
Depressive Disorder
Interventions
saredutant (SR48968), placebo, escitalopram
Drug
Lead sponsor
Sanofi
Industry
Eligibility
60 Years to 64 Years
Enrollment
393 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 23, 2016 · Synced Jun 9, 2026, 11:40 PM EDT
Recruiting Phase 3 Interventional

A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis

NCT07250802
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Zasocitinib, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
4 Years to 17 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
11
States / cities
Chula Vista, California • Fountain Valley, California • Hialeah, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Jun 9, 2026, 11:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase1a, Dose-escalation Study of NNI-362 in Healthy Aged Volunteers

NCT04074837
View directory record Official record
Conditions
Alzheimer Disease
Interventions
NNI-362, Placebo
Drug
Lead sponsor
Neuronascent, Inc.
Industry
Eligibility
50 Years to 72 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Jun 9, 2026, 11:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Pharmacokinetics of ASP1941 and the Effect on Glucose Concentrations in Male and Female Young and Elderly Healthy Adults

NCT01678287
View directory record Official record
Conditions
Healthy Volunteers, Pharmacokinetics of ASP1941
Interventions
ASP1941, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Sep 4, 2012 · Synced Jun 9, 2026, 11:40 PM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate Cinacalcet in Children With Chronic Kidney Disease

NCT01290029
View directory record Official record
Conditions
Chronic Kidney Disease, Hyperparathyroidism, Secondary, Secondary Hyperparathyroidism
Interventions
Cinacalcet
Drug
Lead sponsor
Amgen
Industry
Eligibility
28 Days to 2190 Days
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
4
States / cities
Los Angeles, California • San Francisco, California • Louisville, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Jun 9, 2026, 11:40 PM EDT
Completed Phase 3 Interventional Results available

This Trial, Evaluating the Long-term Safety and Tolerability of Brivaracetam Will Provide Subjects Suffering From Epilepsy, Who May Have Benefited From Brivaracetam as Adjunctive Treatment, the Opportunity to Receive Open Label Brivaracetam Treatment

NCT00150800
View directory record Official record
Conditions
Epilepsy
Interventions
Brivaracetam
Drug
Lead sponsor
UCB PHARMA Inc. (US)
Industry
Eligibility
16 Years and older
Enrollment
668 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
46
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 38 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2021 · Synced Jun 9, 2026, 11:40 PM EDT
Recruiting Phase 3 Interventional

Safety and Preliminary Efficacy of TSHA-102 Gene Therapy in Pediatric Females Aged >2 to <4 Years With Rett Syndrome

NCT07480564
View directory record Official record
Conditions
Rett Syndrome
Interventions
TSHA-102
Genetic
Lead sponsor
Taysha Gene Therapies, Inc.
Industry
Eligibility
2 Years to 3 Years · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jun 9, 2026, 11:40 PM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetics and Pharacodynamics of GW642444 in Paedetric Subjects

NCT01453296
View directory record Official record
Conditions
Asthma
Interventions
GW642444, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
5 Years to 11 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
5
States / cities
Cypress, California • Huntington Beach, California • Denver, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Jun 9, 2026, 11:40 PM EDT
Completed Phase 3 Interventional

Safety, Tolerability and Efficacy of the Transdermal System in Elderly Subjects With Major Depression

NCT00285766
View directory record Official record
Conditions
Major Depression
Interventions
Selegiline Transdermal System
Drug
Lead sponsor
Somerset Pharmaceuticals
Industry
Eligibility
65 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
15
States / cities
Chula Vista, California • San Diego, California • Upland, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2008 · Synced Jun 9, 2026, 11:40 PM EDT